This article is more than 5 years old. Information may no longer be current.

HA hydrogel from Fidia Pharma USA receives product-specific J-code from CMS

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Fidia Pharma USA Inc. announced CMS has given Hymovis a unique J-code.

According to a company press release, the J-code gives health care professionals who use the highly viscoelastic, non-crosslinked hydrogel reimbursement coding and becomes effective as of Jan. 1, 2017.

The product was bioengineered to increase lubrication and shock absorption properties. Hymovis reportedly results in hyaluronan similar to that found in the synovial fluid in the joints. “Hymovis is a true innovation in [hyaluronic acid] HA viscosupplementation,” Aldo Donati, president of Fidia Pharma USA Inc., said in the release. “Its unique molecular structure results in enhanced biomechanical properties and long-lasting efficacy, all in a convenient two-dose regimen. We are excited that the CMS has issued a unique J-code for Hymovis. This will facilitate reimbursement and ensure greater access to this unique viscoelastic technology.”  

Reference:

www.fidiapharma.com